Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996447 | 1.00 | ALDH1A1 (0.60) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 | |
| SCHEMBL1997498 | 0.95 | CYP3A4 (0.61) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 | |
| SCHEMBL1999859 | 0.94 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 | |
| SCHEMBL1998155 | 0.94 | ALDH1A1 (0.57) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 | |
| SCHEMBL2006723 | 0.94 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 | |
| SCHEMBL2003574 | 0.92 | ALDH1A1 (0.54) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 | |
| SCHEMBL2253107 | 0.91 | ALDH1A1 (0.53) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 | |
| SCHEMBL1994810 | 0.91 | ALDH1A1 (0.55) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 | |
| SCHEMBL1996777 | 0.91 | ALDH1A1 (0.58) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 | |
| SCHEMBL1995595 | 0.91 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP3A4CYP2D6CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785633-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130267706-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-10-10 | — | — | US | disclosed |
| US-8338424-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120219509-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8198304-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110319448-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110201583-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20090069335-A1 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267706-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | ALDH1A1 2899/4885CYP1A2 1577/4885CYP3A4 2788/4885 |
| US-20110201583-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | ALDH1A1 2899/4885CYP1A2 1577/4885CYP3A4 2788/4885 |
| US-20110319448-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | ALDH1A1 2899/4885CYP1A2 1577/4885CYP3A4 2788/4885 |
| US-20120219509-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | ALDH1A1 2899/4885CYP1A2 1577/4885CYP3A4 2788/4885 |
| US-20090069335-A1 | Guanidine-containing compounds useful as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM1 | ALDH1A1 2899/4885CYP1A2 1577/4885CYP3A4 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.